http://www.thisislincolnshire.co.uk/displayNode.jsp?nodeId=206844&command=displayContent&sourceNode=156277&contentPK=18082080&folderPk=87018&pNodeId=201408Legal blow for Alzheimer's patients
01:13 - 11 August 2007
Campaigners battling for Alzheimer's sufferers to have access to anti-dementia drugs on the NHS in the early stages of the disease have suffered a High Court blow.
Although a judge ordered the Government's medicines watchdog to amend "discriminatory" guidance on drug treatment for Alzheimer's, the ruling did not pave the way for funding for all patients with "mild" symptoms.
(SNIP)
Alzheimer's Society chief executive Neil Hunt said patients would now have "much fairer access to Alzheimer's drug treatments". However, he added: "But the ruling still falls short of ensuring that everyone with Alzheimer's disease can have access to the drugs."
Last year Nice, backed by an appeal panel, decided that three acetyl cholinesterase inhibitors (AChEIs) - Aricept, Reminyl and Exelon - should no longer be made available on the NHS in the early stages of Alzheimer's. It recommended use of the drugs for "moderate" Alzheimer's, but not for mild cases.
It decided that the drugs, which cost about £2.50 per person a day, were not cost effective in relation to the benefits they offered to such sufferers and their carers.